Savara Completes Enrollment Of Pivotal Phase 3 IMPALA-2 Trial Of Molgramostim Nebulizer Solution In Autoimmune Pulmonary Alveolar Proteinosis; Expects Top Line Results End Of Q2 2024
Portfolio Pulse from Benzinga Newsdesk
Savara has completed enrollment for its Phase 3 IMPALA-2 trial of Molgramostim nebulizer solution in autoimmune pulmonary alveolar proteinosis, with 164 patients enrolled. The company expects to report top line results by the end of Q2 2024.
June 26, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Savara's completion of enrollment for the Phase 3 IMPALA-2 trial is a positive milestone, with top line results expected by Q2 2024.
The completion of enrollment for the Phase 3 IMPALA-2 trial is a significant milestone for Savara, as it indicates progress in the development of Molgramostim nebulizer solution. Positive results from the trial could lead to potential regulatory approval and commercialization, which would positively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100